NOURIN
Live / Registered — Registered (as of 16 Feb 2021)
What this means for you
Registered since 16 Feb 2021. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88768088
- Registration number
- 6274061
- Mark type
- Stylized text
- Filed
- 21 Jan 2020
- Published for opposition
- 09 Jun 2020
- Registered
- 16 Feb 2021
- Attorney of record
- Shuo Che Chou
Goods and services
- Class 001 — Chemicals: protein arrays for research purposes; gene-based RNA molecular network being RNA sequences for research purposes; protein arrays for diagnosing of heart-related diseases angina, heart attack, cardiac and non-cardiac chest pain, heart failure, cardiovascular diseases, acute coronary syndromes, coronary artery disease, ischemic cardiac disease, subclinical or silent ischemia, low-grade myocardial ischemia, heart transplantation for cardiac allograft inflammation, monitor disease progression, severity of heart damage, risk assessment and prognosis, disease progression, myocardial cell damage, patients at-risk for coronary artery disease, and predict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseases, all of the foregoing for research purposes; gene-based RNA molecular network being RNA sequences for diagnosing of heart-related diseases angina, heart attack, cardiac and non-cardiac chest pain, heart failure, cardiovascular diseases, acute coronary syndromes, coronary artery disease, ischemic cardiac disease, subclinical or silent ischemia, low-grade myocardial ischemia, heart transplantation for cardiac allograft inflammation, monitor disease progression, severity of heart damage, risk assessment and prognosis, disease progression, myocardial cell damage, patients at-risk for coronary artery disease, and predict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseases, all of the foregoing for research use; diagnostic biomarker reagents for research purposes; protein arrays of biomarker reagents for research purposes; gene-based RNA molecular network biomarker reagents for research purposes; protein arrays and gene-based RNA molecular network biomarker reagents for research purposes; tissue-derived diagnostic biomarker reagents for research purposes; cardiac-derived diagnostic biomarker reagents for research purposes
- Class 005 — Pharmaceuticals: protein arrays for medical diagnosis purposes; gene-based RNA molecular network being RNA sequences for medical diagnosis purposes; protein arrays for diagnosing of heart-related diseases angina, heart attack, cardiac and non-cardiac chest pain, heart failure, cardiovascular diseases, acute coronary syndromes, coronary artery disease, ischemic cardiac disease, subclinical or silent ischemia, low-grade myocardial ischemia, heart transplantation for cardiac allograft inflammation, monitor disease progression, severity of heart damage, risk assessment and prognosis, disease progression, myocardial cell damage, patients at-risk for coronary artery disease, and predict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseases, all of the foregoing for medical diagnosis purposes; gene-based RNA molecular network being RNA sequences for diagnosing of heart-related diseases angina, heart attack, cardiac and non-cardiac chest pain, heart failure, cardiovascular diseases, acute coronary syndromes, coronary artery disease, ischemic cardiac disease, subclinical or silent ischemia, low-grade myocardial ischemia, heart transplantation for cardiac allograft inflammation, monitor disease progression, severity of heart damage, risk assessment and prognosis, disease progression, myocardial cell damage, patients at-risk for coronary artery disease, and predict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseases, all of the foregoing for medical use; diagnostic biomarker reagents for medical purposes; protein arrays of biomarker reagents for medical diagnosis purposes; gene-based RNA molecular network biomarker reagents for medical diagnosis purposes; protein arrays and gene-based RNA molecular network biomarker reagents for medical diagnosis purposes; tissue-derived diagnostic biomarker reagents for medical purposes; cardiac-derived diagnostic biomarker reagents for medical purposes
Owner
- Nour Heart, Inc., Vienna, VA, US
- Nour Heart, Inc., Vienna, VA, US
- Nour Heart, Inc., Vienna, VA, US
Prosecution history
- 16 Feb 2026 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 16 Feb 2021 — REGISTERED-PRINCIPAL REGISTER
- 15 Jan 2021 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 14 Jan 2021 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 14 Jan 2021 — STATEMENT OF USE PROCESSING COMPLETE
- 22 Dec 2020 — USE AMENDMENT FILED
- 13 Jan 2021 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 22 Dec 2020 — TEAS STATEMENT OF USE RECEIVED
- 04 Aug 2020 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 09 Jun 2020 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 09 Jun 2020 — PUBLISHED FOR OPPOSITION
- 20 May 2020 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 05 May 2020 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 25 Apr 2020 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 24 Apr 2020 — CORRESPONDENCE RECEIVED IN LAW OFFICE